Summit Therapeutics Inc. filed a Form 8-K on September 15, 2026, announcing that updated overall survival results from its global Phase III HARMONi clinical trial were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer.

Key Highlights

  • Trial results presented: Updated overall survival data from the global Phase III HARMONi clinical trial were presented at WCLC 2026 on September 15, 2026.
  • Partner data also presented: Data from the randomized, double-blind Phase III HARMONi-2 trial were presented at WCLC 2026 by the company's partner, Akeso Inc.
  • Press release attached: A press release dated September 15, 2026 is attached as Exhibit 99.1 and incorporated by reference into the filing.
  • Signed by: The filing was signed by Manmeet S. Soni, Chief Operating Officer, Chief Financial Officer and Director.

Summit Therapeutics Discloses Phase III HARMONi Overall Survival Results at WCLC 2026

According to the filing, Summit Therapeutics Inc. (NASDAQ:SMMT), headquartered at 601 Brickell Key Drive, Suite 1000, Miami, FL 33131, issued a press release on September 15, 2026, disclosing that updated overall survival results from the global Phase III HARMONi clinical trial were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer, referred to in the filing as WCLC 2026.

The filing also notes, according to the press release, that data from the randomized, double-blind Phase III HARMONi-2 trial were presented at WCLC 2026 by Akeso Inc., identified in the filing as the company's partner. The 8-K was filed under Item 8.01 (Other Events) and does not include financial statements. The complete press release containing the clinical data details is attached as Exhibit 99.1 and incorporated by reference into the Current Report.

The report was signed on behalf of Summit Therapeutics Inc. by Manmeet S. Soni in his capacity as Chief Operating Officer, Chief Financial Officer and Director, identified in the filing as the Principal Financial Officer. The company's common stock, with a par value of $0.01 per share, trades on The Nasdaq Stock Market LLC under the trading symbol SMMT.

What Was Disclosed

Summit Therapeutics filed an 8-K on September 15, 2026, disclosing the presentation of updated overall survival results from its Phase III HARMONi trial and partner Akeso Inc.'s Phase III HARMONi-2 trial data at WCLC 2026. The full data details are contained in the attached press release, Exhibit 99.1.